<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907959</url>
  </required_header>
  <id_info>
    <org_study_id>BZL-101-003</org_study_id>
    <nct_id>NCT00907959</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer</brief_title>
  <official_title>A Phase 2 Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionovo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionovo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' proposed phase 2 clinical trial will be an open-label, non-randomized&#xD;
      study among 80 women with metastatic breast cancer. The study treatment period will be up to&#xD;
      twelve months and enrollment will be open at 10-15 clinical sites in the United States. In&#xD;
      this Phase 2 trial, 40 participants with hormone receptor positive tumors and 40 with hormone&#xD;
      receptor negative tumors will be enrolled and treated with BZL101 20 grams/day (10 grams&#xD;
      BID). Hormone receptor positive will be defined as estrogen receptor (ER)+ and progesterone&#xD;
      receptor (PR)+, ER+ and PR-, or ER- and PR+. Hormone receptor negative will be defined as ER-&#xD;
      and PR-.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcomes of the Phase 2 trial will be safety and toxicity as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and tumor response rate defined by new RECIST criteria 1.1.</measure>
    <time_frame>Monthly</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BZL101</intervention_name>
    <description>Oral BZL101 20 grams/day (10 grams BID).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women 18 years or older.&#xD;
&#xD;
          2. Histologically confirmed diagnosis of breast cancer based on pathology report of&#xD;
             primary, regional or metastatic breast cancer.&#xD;
&#xD;
          3. Clinical evidence of metastatic (stage IV) involvement other than bone only metastasis&#xD;
             based on the investigator's clinical and/or radiographic findings.&#xD;
&#xD;
          4. Availability of estrogen receptor and progesterone receptor status measured on biopsy&#xD;
             tissue. (Status on the most recent biopsy where ER/PR status was documented will be&#xD;
             used to determine hormone receptor status for stratification).&#xD;
&#xD;
          5. At least one measurable disease site defined by RECIST criteria, with measurement made&#xD;
             within 30 days of beginning study therapy. (Non-measurable disease includes bone&#xD;
             lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory&#xD;
             breast disease, lymphangitis cutis/pulmonis, abdominal masses that are not confirmed&#xD;
             and followed by imaging techniques, and cystic lesions. For lesions in a previously&#xD;
             irradiated field, the radiated lesion cannot be assessed as a measurable lesion unless&#xD;
             growth of that lesion has been documented after radiation).&#xD;
&#xD;
          6. No more than 2 prior cytotoxic regimens administered for metastatic breast cancer.&#xD;
             (Participants may have received any number of exogenous hormone therapies for Stage IV&#xD;
             disease and/or adjuvant therapy).&#xD;
&#xD;
          7. Life expectancy of &gt;12 weeks.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group performance status &lt;2.&#xD;
&#xD;
          9. Women of child bearing potential must agree to use two adequate methods of&#xD;
             contraception or abstain from sexual intercourse during study treatment. Acceptable&#xD;
             methods of contraception are as follows:&#xD;
&#xD;
               1. Intrauterine device (IUD)&#xD;
&#xD;
               2. Hormonal birth control&#xD;
&#xD;
               3. Tubal ligation&#xD;
&#xD;
               4. Partner's vasectomy&#xD;
&#xD;
               5. Latex condom&#xD;
&#xD;
               6. Diaphragm&#xD;
&#xD;
               7. Cervical cap&#xD;
&#xD;
         10. Adequate organ and marrow function measured within 14 days of study treatment as&#xD;
             defined below:&#xD;
&#xD;
        Absolute neutrophil count &gt;1,500 cells/mm3 Platelets &gt;100,000 cells/mm3 Hemoglobin &gt;10 g/dL&#xD;
        Total bilirubin &lt;1.5 mg/dL AST(SGOT)/ALT(SGPT) &lt;2.5 X institutional upper limit of normal&#xD;
        or &lt;5 X normal with documented liver metastasis Alkaline Phosphatase &lt;3 X institutional&#xD;
        upper limit of normal or &lt;5 X normal with documented liver or bone metastasis Serum&#xD;
        creatinine &lt;1.5 mg/dL or Creatinine clearance &gt;60 mL/min/1.73 m2 for participants with&#xD;
        serum creatinine levels above institutional normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary Tagliaferri, MD</last_name>
    <phone>5106012000</phone>
    <email>mary@bionovo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Banu Arun, MD</last_name>
      <phone>713-792-2817</phone>
      <email>barun@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Banu Arun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>May 22, 2009</study_first_submitted>
  <study_first_submitted_qc>May 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <name_title>Mary Tagliaferri, Chief Medical Officer</name_title>
    <organization>Bionovo</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

